It is the cache of http://www.dovepress.com/benefits-of-statin-therapy-and-compliance-in-high-risk-cardiovascular--a5358. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Benefits of statin therapy and compliance in high risk cardiovascular
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14853

Benefits of statin therapy and compliance in high risk cardiovascular patients



Review

(11216) Total Article Views


Authors: Joel A Lardizabal, Prakash C Deedwania

Published Date September 2010 Volume 2010:6 Pages 843 - 853
DOI: http://dx.doi.org/10.2147/VHRM.S9474

Joel A Lardizabal1, Prakash C Deedwania2
1Division of Cardiology, Department of Medicine, University of California in San Francisco (Fresno-MEP), Fresno, CA, USA; 2University of California in San Francisco, Chief of Cardiology, Veterans Affairs Central California System, Fresno, CA, USA

Abstract: Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the advantage of statin treatment in other high-risk CVD conditions, such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the management of these CVD conditions all advocate for the utilization of statin therapy in appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, physician-, and economic-related factors all play a role. These factors need to be considered in devising approaches to enhance adherence to guideline-based therapies. To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged.

Keywords: cardiovascular disease, statin therapy, coronary heart disease, long-term treatment compliance


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Prakash Deedwania


Readers of this article also read:

  • ACC 2014

    We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.

  • Like us on Facebook

    Click the blue link above to become a part of our Facebook community.